Stephane Wenric, PhD

GENOMICS, ONCOLOGY, BIOINFORMATICS & COMPUTATIONAL BIOLOGY EXPERT

Experienced computational biologist and team lead with a strong scientific and technical background including 15 years of expertise in genomics/transcriptomics, clinical data and oncology, machine learning and statistics, and client-facing experience.

I currently work as a Lead Bioinformatics Scientist at Natera.

Previously, I held various Computational Biology roles at Tempus; and before that, I was a Postdoctoral Fellow at the Icahn School of Medicine at Mount Sinai, NY.

I hold a PhD in Biomedical Sciences (bioinformatics, cancer genomics) and a master's degree in Biomedical Engineering from the University of Liège

I have authored 15+ publications in peer-reviewed scientific journals, two US patents, one European patent, I have presented scientific results at several international conferences, and I have received more than $100K in research grants and academic excellence awards, including a BAEF Fellowship.

Research

I apply machine learning, statistics, algorithmics, and software engineering methods to data arising from cancer genomics/transcriptomics and population genomics related questions.

As the modern genomic and transcriptomic techniques yield vast amounts of data, machine learning methods are well suited to tackle problems taking roots in these fields.

My past and present research projects include using circulating miRNAs as cancer biomarkers, studying the global disruption of antisense long non-coding RNAs in breast cancer samples, analyzing real-time pharmacogenetics phenotypes in ancestrally diverse populations, using graph theory analysis on Identity-By-Descent networks, developing novel (machine learning based) feature selection and gene prioritization methods, implementing RNA based subtyping models for pancreatic ductal adenocarcinoma.

My activities have led me to work in research, clinical, and industry settings.

Publications

See Google Scholar for a full publication list, including consortium and group authorships, and pre-prints.

Selected Peer-reviewed journal articles & pre-prints

First author publications are underlined

Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma.

JCO Precision Oncology. 2025.

Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.

Breast Cancer Research. 2023.

Privacy preserving validation for multiomic prediction models.

Briefings in Bioinformatics. 2022.

Toward a fine-scale population health monitoring system.

Cell. 2021.

EPS: Automated Feature Selection in Case-Control Studies using Extreme Pseudo-Sampling.

Bioinformatics. 2021.

Rapid response to the Alpha-1 Adrenergic Agent Phenylephrine in the Perioperative Period is Impacted by Genomics and Ancestry.

The Pharmacogenomics Journal. 2020.

VPS51 biallelic variants cause microcephaly with brain malformations: A confirmatory report.

European Journal of Medical Genetics. 2019.

Variations of circulating biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.

BMC Cancer. 2018.

Using supervised learning methods for gene selection in RNA-Seq case-control studies.

Frontiers in Genetics. 2018.

Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer.

Scientific Reports. 2017.

Exome Copy Number Variation detection: use of a pool of unrelated healthy tissue as reference sample.

Genetic Epidemiology. 2016.

Genomic Studies of Multiple Myeloma Reveal an Association between X Chromosome Alterations and Genomic Profile Complexity.

Genes, Chromosomes and Cancer. 2016.

Circulating microRNA-based screening tool for breast cancer.

Oncotarget. 2015.

Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.

BMC Cancer. 2015.

Patents

Quantifying effects of sequencing variance on classification

US Patent pending. US20250285704A1. 2024.

Systems and Methods for Homogenization of Disparate Datasets.

US Patent pending. US20220059190A1. 2021.

Method for the diagnosis of breast cancer.

European Patent. EP2942399. 2025.

Conferences

Real-world validation of the PurIST classifier demonstrates enhanced therapy selection for pancreatic ductal adenocarcinoma (PDAC) patients.

American Association for Cancer Research (AACR) annual meeting. 2024.

Purity Independent Subtyping of Tumor (PurIST): Real-world data validation of a pancreatic ductal adenocarcinoma (PDAC) gene expression classifier and its prognostic implications.

American Association for Cancer Research (AACR) special conference on Pancreatic Cancer. 2022.

Genomic and transcriptomic comparison between breast cancers from patients of African and European genetically determined ancestries demonstrates potential for ancestry specific biomarker-informed therapies.

American Association for Cancer Research (AACR) annual meeting. 2022.

Transferring diagnostic and prognostic molecular models across technological platforms.

American Association for Cancer Research (AACR) annual meeting. 2021.

Towards cancer mega-cohorts: A novel homogenization algorithm applied to diverse breast cancer RNA-Seq datasets.

American Society of Clinical Oncology (ASCO) annual meeting. 2020.

Rapid response to the Alpha-1 Adrenergic Agent Phenylephrine in the Perioperative Period is Impacted by Genomics and Ancestry.

6th Human Genetics in NYC Conference. 2018.

A new paradigm for pharmacogenomic discoveries: Capturing drug response during surgery.

American Society of Human Genetics (ASHG) annual meeting. 2018.

Capturing drug response during surgery for pharmacogenomic discoveries.

5th Human Genetics in NYC Conference. 2018.

Antisense long non-coding RNAs in breast cancer: A transcriptome-wide disruption.

American Society of Human Genetics (ASHG) annual meeting. 2017.

Transcriptome wide analysis of natural antisense transcripts shows their potential role in breast cancer.

European Conference of Human Genetics (ESHG). 2017.

A miRNA expression based diagnostic tool for breast cancer using random forests.

Benelux Bioinformatics Conference. 2013.

Exome sequencing of tumors: relevance in copy-number alteration (CNA) analysis and fixed tissue samples.

Benelux Bioinformatics Conference. 2013.

Resume

Download a PDF version of my resume: